Green Thumb's quarterly revenue grew 4.6% during the quarter, while comps declined 1.1%, reflecting weak retail health of its existing stores. While the company's revenue grew consistently over the past 5 years, its EBITDA margin remained under pressure over the same period due to stiff competition. Overall, I give Green Thumb a buy rating. Low debt level, aggressive share buybacks, and Schedule III reclassification are strong reasons to commit your capital.
On Tuesday, Green Thumb Industries GTBIF reported impressive second-quarter 2026 results, with earnings and sales beating consensus estimates.
Green Thumb Industries Inc. (GTBIF) Q2 2026 Earnings Call Transcript
| Health Care Equipment & Supplies Industry | Healthcare Sector | Benjamin Kovler CEO | XSTU Exchange | CA39342L1085 ISIN |
| US Country | 5,000 Employees | - Last Dividend | 7 Jan 2010 Last Split | - IPO Date |
Green Thumb Industries Inc. is a leading entity in the cannabis industry within the United States, focusing on the manufacturing, distribution, marketing, and sales of cannabis products. The company caters to both medical and adult-use markets and operates through two primary segments: Retail and Consumer Packaged Goods. Founded in 2014, with its headquarters in Chicago, Illinois, Green Thumb Industries has been at the forefront of expanding access to safe and effective cannabis products across the nation. The company's operations include not only the supply of cannabis flower and processed products but also the ownership and management of retail stores and direct-to-consumer delivery services. This integrated approach allows Green Thumb to maintain strict quality control, ensuring that consumers receive premium products tailored to a variety of needs and preferences.